Metformin for Mind and Metabolism

Phase 4

Recruiting

• Conditions: Depression; Abdominal Obesity; Mental Health - Depression; Diet and Nutrition - Obesity

• Registration Number: ACTRN12613000856718
• Lead Sponsor: The Alfred Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-08-02
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

adults aged 18-65
ongoing symptoms of depression (MADRS>10) despite at least 8 weeks on a stable dose of an antidepressant
adbominal obesity (waist circumference >88cm for women or 102cm for men)

Exclusion Criteria

renal impairment (eGFR<60)
suicidal
psychotic disorders
diabetes mellitus
allergy to metformin, lactose or other component of metformin or placebo formulations

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
severity of depression as assessed using the MADRS (Montgomery Asperg Depression Rating Scale)[12 weeks]

Secondary Outcome Measures

Name	Time	Method
change in cognition as measured by CogState (computer based cognitive testing)[12 weeks];change in weight as determined by using calibrated digital scales[12 weeks]